BEFORE THE

INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE AND APPLICATION REVIEW SUBCOMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

REGULAR MEETING

LOCATION: AS INDICATED ON THE AGENDA

DATE: WEDNESDAY, OCTOBER 19, 2016

11 A.M.

REPORTER: BETH C. DRAIN, CSR

CSR. NO. 7152

BRS FILE NO.: 99020

INDEX

ITEM DESCRIPTION	PAGE NO
CALL TO ORDER	3
ROLL CALL	3
CONSIDERATION OF APPLICATIONS SUBMITTED IN RESPONSE TO INFR2: PARTNERING OPPORTUNITY TO CREATE A CIRM TRANSLATING CENTER	4
ADJOURNMENT	13

2

```
1
 2
             WEDNESDAY, OCTOBER 19, 2016; 11 A.M.
 3
 4
               CHAIRMAN THOMAS: GOOD MORNING, EVERYBODY.
 5
     WELCOME TO THE OCTOBER MEETING OF THE ICOC AND
 6
     APPLICATION REVIEW SUBCOMMITTEE. CALLING THE
 7
     MEETING TO ORDER. MARIA, WILL YOU PLEASE CALL THE
 8
     ROLL.
 9
               MS. BONNEVILLE: DAVID BRENNER. KEN
     BURTIS. DEBORAH DEAS. ANNE-MARIE DULIEGE. HOWARD
10
11
     FEDEROFF. MICHAEL FRIEDMAN. JUDY GASSON. SAM
12
     HAWGOOD. DAVID HIGGINS.
13
               DR. HIGGINS: HERE.
14
               MS. BONNEVILLE: STEPHEN JUELSGAARD.
15
               MR. JUELSGAARD: HERE.
16
               MS. BONNEVILLE: SHERRY LANSING. KATHY
17
     LAPORTE.
18
               DR. LAPORTE: HERE.
19
               MS. BONNEVILLE: BERT LUBIN. SHLOMO
20
     MELMED.
              LAUREN MILLER.
21
               MS. MILLER: HERE.
22
               MS. BONNEVILLE: LLOYD MINER. ADRIANA
23
     PADILLA.
24
               DR. PADILLA: HERE.
25
               MS. BONNEVILLE: JOE PANETTA. FRANCISCO
                               3
```

1	PRIETO. CARMEN PULIAFITO. ROBERT QUINT.
2	DR. QUINT: HERE.
3	MS. BONNEVILLE: AL ROWLETT.
4	MR. ROWLETT: HERE.
5	MS. BONNEVILLE: JEFF SHEEHY.
6	MR. SHEEHY: HERE.
7	MS. BONNEVILLE: OSWALD STEWARD.
8	DR. STEWARD: HERE.
9	MS. BONNEVILLE: JONATHAN THOMAS.
10	CHAIRMAN THOMAS: HERE.
11	MS. BONNEVILLE: ART TORRES.
12	MR. TORRES: HERE.
13	MS. BONNEVILLE: KRISTINA VUORI. DIANE
14	WINOKUR.
15	MS. WINOKUR: HERE.
16	MS. BONNEVILLE: THANK YOU.
17	CHAIRMAN THOMAS: THANK YOU, MARIA. GOING
18	ON TO ITEM 3. AS THIS IS THE APPLICATION REVIEW
19	SUBCOMMITTEE, WE'RE NOW GOING TO PROGRAMMATIC
20	REVIEW. SO I WILL TURN THE MEETING OVER TO MR.
21	SHEEHY.
22	MR. SHEEHY: THANK YOU, J.T.
23	SO WE HAVE SHALL WE GO INTO A
24	PRESENTATION? IS THAT HOW WE SHOULD START THIS? SO
25	DR. SAMBRANO.
	4

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	DR. SAMBRANO: THANK YOU, JEFF.
2	SO GOOD MORNING, EVERYONE. I'M GOING TO
3	JUST GIVE AN OVERVIEW ON THE TRANSLATING CENTER
4	REVIEW AND THE RECOMMENDATIONS THAT ARE COMING FROM
5	THE GWG RELATED TO THAT. I'M ALSO GOING TO GO OVER
6	SOME OF THE SLIDES THAT WERE DISTRIBUTED. THEY
7	WON'T BE NECESSARY IN ORDER TO FOLLOW THE
8	PRESENTATION.
9	SO WE HAVE THREE PROGRAMS UNDER
10	INFRASTRUCTURE THAT WE'VE BEEN PUTTING TOGETHER THAT
11	INCLUDE THE ALPHA CLINICS NETWORK, THE ACCELERATING
12	CENTER, WHICH JUST RECENTLY LAUNCHED, AND THE
13	ACCELERATING CENTER, OF COURSE, FOCUSED ON HELPING
14	WITH THE REGULATORY AND LATER STAGE CLINICAL TRIAL
15	MANAGEMENT ASPECT. AND NOW WE'RE LOOKING TO LAUNCH
16	A TRANSLATING CENTER WHICH WILL COMPLEMENT BOTH
17	OTHER INFRASTRUCTURE PROGRAMS WITH THE GOAL OF
18	SHORTENING THE TIME TO GET TO CLINICAL TESTING.
19	AND THE ACTIVITIES THAT THEY PICTURE WILL
20	BE INVOLVED: PROCESS DEVELOPMENT, IND-ENABLING
21	ACTIVITIES, AND PRECLINICAL RESEARCH.
22	THE TRANSLATING CENTER WILL BE A
23	CIRM-FUNDED STEM CELL PRECLINICAL RESEARCH
24	ORGANIZATION THAT WILL HAVE \$15 MILLION OF SUPPORT
25	OVER FIVE YEARS, AND IT WILL OPERATE WITHIN

1	CALIFORNIA. AND THERE ARE SIX BASIC CORE SERVICES
2	THAT ARE ENCOMPASSED UNDER THE TRANSLATING CENTER,
3	WHICH INCLUDE CONSULTATION SERVICES, PROJECT
4	MANAGEMENT, PRECLINICAL DEVELOPMENT RESEARCH,
5	PROCESS DEVELOPMENT, AND MANUFACTURING, AS WELL AS
6	REGULATORY FILING SUPPORT. AND THESE SERVICES WILL
7	BE PROPORTIONAL TO THE NEEDS OF THE PROJECT, MEANING
8	A CLIENT CAN UTILIZE WHATEVER SERVICES THEY NEED TO
9	ADDRESS WHATEVER GAPS THEY FEEL THEY HAVE AS THEY
10	WORK WITH THESE CENTERS IN ORDER TO ACCELERATE THEIR
11	PROGRAM.
12	THE PROGRAM OR THE TRANSLATING CENTER IS
13	EXPECTED TO BE SUSTAINABLE AS WELL. SO OVER THE
14	COURSE OF THE FIVE YEARS THAT WE WILL PROVIDE
15	SUPPORT, WE HOPE THAT THEY WILL DEVELOP A PROGRAM
16	THAT IS ATTRACTIVE AND THAT BRINGS IN ENOUGH
17	CLIENTELE TO BE SELF-SUPPORTING SO THAT ONCE CIRM
18	FUNDING ENDS, THAT THIS IS A RESOURCE THAT WILL
19	CONTINUE TO BE AVAILABLE TO THE COMMUNITY AND STILL
20	EXIST.
21	ON THE NEXT SLIDE, WHICH IS THE GRANTS
22	WORKING GROUP REVIEW CRITERIA, THIS IS JUST GOING
23	OVER WHAT CRITERIA THE GWG UTILIZED AND HOW WE
24	PRESENTED IT TO THEM IN TERMS OF HOW TO REVIEW THESE
25	APPLICATIONS. AND THEY BOIL DOWN TO THREE BASIC

1	CRITERIA.
2	THE FIRST IS DOES THE PROPOSED CENTER HOLD
3	THE NECESSARY SIGNIFICANCE AND POTENTIAL FOR IMPACT;
4	THAT IS, HOW LIKELY IS THE PROPOSED CENTER TO
5	ACCELERATE PROGRESSION OF STEM CELL PROJECTS FROM
6	LATE PRECLINICAL STAGE TO IND FILING AND CONDUCT OF
7	THE CLINICAL TRIAL? DOES IT OFFER A SUFFICIENT
8	IMPACTFUL AND PRACTICAL VALUE PROPOSITION FOR
9	RESEARCHERS, FOR PATIENTS, OR HEALTHCARE PROVIDERS
10	BY INCREASING THE SPEED AND QUALITY OF THE
11	PRECLINICAL STAGE PROJECT. SO THAT'S THE FIRST ONE.
12	SECOND ONE, HAS THE APPLICANT DEVELOPED A
13	PLAN TO SUCCESSFULLY ESTABLISH AND OPERATIONALIZE
14	THE CENTER? THEN WE WANT TO KNOW HOW WELL THEY
15	INTEGRATE WITH THE ACCELERATING CENTER THAT WE'VE
16	ALREADY SUPPORTED. ARE THE OPERATIONS APPROPRIATELY
17	PLANNED AND DESIGNED TO EXECUTE MEANINGFUL,
18	ACCELERATING, AND IMPACTFUL RESOURCES; THAT IS, THE
19	CORE SERVICES THAT I PREVIOUSLY DESCRIBED. DO THEY
20	HAVE AN APPROPRIATE PROJECT PLAN AND TIMELINE FOR
21	ESTABLISHING THE CENTER? AND DO THEY HAVE A GOOD
22	PLAN FOR COMPETITIVE PRICING WHILE ENSURING
23	SUSTAINABILITY OF THE CENTER BEYOND FIVE YEARS.
24	AND THEN THE THIRD, IS THE PROPOSAL
25	FEASIBLE; THAT IS, IS THE CENTER LIKELY TO BE
	_

7

1	ESTABLISHED WITHIN THE PROPOSED TIMELINE? IS THE
2	TEAM APPROPRIATELY QUALIFIED AND STAFFED? DO THEY
3	HAVE ALL THE NECESSARY RESOURCES TO ACCOMPLISH WHAT
4	THEY PROPOSE? AND DO THEY HAVE A VIABLE CONTINGENCY
5	PLAN TO MITIGATE TO MANAGE RISK AND DELAYS? SO
6	THAT'S THE REVIEW CRITERIA.
7	THE OTHER THING THAT WE UTILIZED IN THIS
8	REVIEW, WHICH WE INTRODUCED IN THE ACCELERATING
9	CENTER, WAS THE PITCH. SO THAT MEANS THAT APPLICANT
10	TEAMS WERE INVITED TO BE FACE TO FACE WITH THE GWG
11	AND GIVE A 15-MINUTE PRESENTATION TO ADDRESS THE
12	BIG-PICTURE POINTS OF THEIR PROPOSAL, THE VISION,
13	HOW THEY WILL MAINTAIN AND ESTABLISH SUSTAINABILITY,
14	AND WHAT THE OVERALL VALUE PROPOSITION OF THE
15	TRANSLATING CENTER IS GOING TO BE. THE GWG HAD AN
16	OPPORTUNITY TO ASK QUESTIONS DIRECTLY OF TEAM
17	MEMBERS, AND SO THAT WAS EXTENSIVELY UTILIZED AS WE
18	WERE HAPPY TO SEE.
19	THE NEXT SLIDE IS THE DESCRIPTION OF THE
20	SCORING SYSTEM, WHICH IS, JUST BRIEFLY, THE 1 TO 100
21	SCALE, WITH 85 BEING THE CUTOFF. EIGHTY-FIVE OR
22	ABOVE MEANING EXCEPTIONAL MERIT AND WARRANTS
23	FUNDING. IN THIS CASE, BECAUSE IT'S AN
24	INFRASTRUCTURE PROGRAM UNDER THE RULES THAT WERE
25	ESTABLISHED FOR THIS PARTICULAR ONE, ONLY THE
	0
	8

1	APPLICATION WITH THE HIGHEST AVERAGE SCORE IS
2	RECOMMENDED FOR FUNDING.
3	ON THE NEXT SLIDE IS JUST THE FINAL VOTE
4	THAT WE TAKE AT THE END OF EACH REVIEW FOR THE RIGOR
5	OF THE PROCESS AND THE OVERALL FAIRNESS. AND THE
6	VOTE TAKEN BY THE GWG AND PATIENT ADVOCATE MEMBERS
7	WAS UNANIMOUS IN TERMS OF HAVING AN APPROPRIATE
8	PROCESS.
9	AND THEN THE NEXT SLIDE SHOWS A TABLE OF
10	THE APPLICATIONS THAT WERE RECEIVED AND REVIEWED.
11	SO WE HAD A TOTAL OF FOUR APPLICATIONS THAT WERE
12	ACCEPTED FOR REVIEW AND UNDERWENT REVIEW. THERE WAS
13	ONE APPLICATION THAT SCORED BETWEEN 85 AND 100; AND,
14	THEREFORE, IT WAS RECOMMENDED FOR FUNDING, AND THERE
15	WERE THREE THAT WERE NOT OF THE THREE TO HAVE
16	WITHDRAWN. AND SO WHAT IS AVAILABLE TO YOU IN TERMS
17	OF REVIEW SUMMARIES ON THE SUMMARIES FOR THE TWO
18	THAT REMAIN, ONE WAS THAT RECOMMENDED AND ONE THAT
19	WAS NOT.
20	AND ON THE NEXT SLIDE WE HAVE THE OVERVIEW
21	OF THE FIRST APPLICATION, WHICH IS THE RECOMMENDED
22	ONE, 9298, WHICH RECEIVED A SCORE OF 89 WITH A
23	MEDIAN OF 90. THE CIRM TEAM ALSO RECOMMENDS THIS
24	APPLICATION FOR FUNDING WITH AN AWARD AMOUNT OF 15
25	MILLION. AND I WILL STOP THERE FOR ANY QUESTIONS.

1	MR. SHEEHY: SO DO WE HAVE ANY QUESTIONS?
2	SO DO WE HAVE A MOTION TO ACCEPT THE TEAM
3	RECOMMENDATION AND FUND THE APPLICATION 09298?
4	MR. TORRES: SO MOVED.
5	DR. STEWARD: SECOND.
6	CHAIRMAN THOMAS: SECONDED BY DR. STEWARD.
7	ANY ADDITIONAL DISCUSSION?
8	MS. HARRISON: IT'S JAMES. JUST ONE
9	CLARIFICATION. DOES THIS MOTION INCORPORATE NOT
10	APPROVING THE SECOND APPLICATION, 9233?
11	MR. TORRES: YES.
12	MR. SHEEHY: YES. OS?
13	DR. STEWARD: YES FROM THE SECOND.
14	MR. SHEEHY: YES, IT DOES. ANY PUBLIC
15	COMMENT AT ANY OF THE SITES? COULD WE CALL THE ROLL
16	THEN, PLEASE.
17	MS. BONNEVILLE: ANNE-MARIE DULIEGE.
18	DAVID HIGGINS.
19	DR. HIGGINS: YES.
20	MS. BONNEVILLE: STEVE JUELSGAARD.
21	MR. JUELSGAARD: YES.
22	MS. BONNEVILLE: SHERRY LANSING. KATHY
23	LAPORTE.
24	MS. LAPORTE: YES.
25	MS. BONNEVILLE: LAUREN MILLER.
	10
	10

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

1	MS. MILLER: YES.
2	MS. BONNEVILLE: ADRIANA PADILLA.
3	DR. PADILLA: YES.
4	MS. BONNEVILLE: JOE PANETTA. FRANCISCO
5	PRIETO. ROBERT QUINT.
6	DR. QUINT: YES.
7	MS. BONNEVILLE: AL ROWLETT.
8	MR. ROWLETT: YES.
9	MS. BONNEVILLE: JEFF SHEEHY.
10	MR. SHEEHY: YES.
11	MS. BONNEVILLE: OS STEWARD.
12	DR. STEWARD: YES.
13	MS. BONNEVILLE: JONATHAN THOMAS.
14	CHAIRMAN THOMAS: YES.
15	MS. BONNEVILLE: ART TORRES.
16	MR. TORRES: AYE.
17	
	MS. BONNEVILLE: DIANE WINOKUR.
18	MS. WINOKUR: YES.
19	MS. BONNEVILLE: MOTION CARRIES.
20	MR. SHEEHY: GREAT. THANK YOU.
21	I WANT TO CONGRATULATE THE CIRM TEAM ON
22	PUTTING IN PLACE THIS LAST PIECE OF CRITICAL
23	INFRASTRUCTURE TO ACCELERATE US INTO THE CLINIC.
24	AND CONGRATULATE QUINTILES WHICH I THINK WILL GIVE
25	US A SEAMLESS PRODUCT ALL THE WAY FROM TRANSLATION
	11

160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM

THROUGH CLINICAL TRIALS.
THANK YOU TO EVERYBODY ON THE CALL TODAY.
IT'S BACK TO YOU, CHAIRMAN THOMAS.
CHAIRMAN THOMAS: THANK YOU, MR. SHEEHY.
I ECHO YOUR COMMENTS. AND CONGRATULATIONS TO
EVERYBODY WORKING ON THIS. I THINK THIS WILL BE A
TERRIFIC PROGRAM AND BETWEEN IT AND THE ACCELERATING
CENTER WILL PROVIDE WORLD-CLASS SERVICE FOR ALL
THOSE WORKING ALONG THE RESEARCH SPECTRUM IN
CELLULAR THERAPY.
WE HAVE NO OTHER ITEMS ON THE AGENDA.
WE'RE NOW AT PUBLIC COMMENT.
MS. CHEUNG: I JUST WANTED TO SAY
SOMETHING AFTER YOU WERE DONE.
CHAIRMAN THOMAS: NOW PUBLIC COMMENT. IS
THERE ANY MEMBERS OF THE PUBLIC AT ANY OF THE
VARIOUS SITES WHO WOULD LIKE TO GIVE COMMENT ON
ANYTHING AT THIS POINT? HEARING NONE, AMY.
MS. CHEUNG: SO OUR NEXT APPLICATION
SUBCOMMITTEE MEETING IS NOVEMBER 17TH, AND IT'S
GOING TO BE SCHEDULED FOR TWO HOURS. CURRENTLY IT'S
SCHEDULED FROM ELEVEN TO TWELVE, BUT WE WILL GO FROM
ELEVEN TO ONE. SO I WILL SEND AN E-MAIL ABOUT THAT.
YOU'LL SEE AN E-MAIL FROM ME SHORTLY.
CHAIRMAN THOMAS: THANK YOU VERY MUCH.
12


12

```
THAT CONCLUDES THIS MEETING. THANK YOU, EVERYBODY.
 1
 2
     AND, LADIES AND GENTLEMEN, HAVE A PLEASANT REST OF
 3
      YOUR DAY. WE STAND ADJOURNED.
 4
                      (THE MEETING WAS THEN CONCLUDED AT
 5
      11:16 AM.)
 6
 7
 8
 9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
                                13
```

REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE TELEPHONIC PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE AND THE APPLICATION REVIEW SUBCOMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS REGULAR MEETING HELD ON OCTOBER 19, 2016, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTERS' REPORTING SERVICE 160 S. OLD SPRINGS ROAD SUITE 270 ANAHEIM, CALIFORNIA (714) 444-4100



160 S. OLD SPRINGS ROAD, SUITE 270, ANAHEIM, CALIFORNIA 92808 1-800-622-6092 1-714-444-4100 EMAIL: DEPO@DEPO1.COM